VERTEX PHARMACEUTICALS INC / MA
VRTXNasdaqGSBiotechnology • Healthcare
Comprehensive AI Analysis
Strategic AI Analysis for VRTX
Checking whether the approved providers contain enough current financial data for a reliable report.
Summary
Source-linked company research for VRTX
Factor Scorecard
Mechanical 0-100 composites from the displayed inputs. Bands and colours are numerical aids, not security ratings or investment actions.
Latest results at a glance
Insights from the latest company results and reports
Quarterly Revenue Growth Accelerates
Revenue for the quarter ended 2026-06-30 was $3.33bn, up 12.45% from $2.96bn for the quarter ended 2025-06-30.
EPS Falls Slightly Below Consensus
Reported EPS of $4.73 per share fell below same-quarter consensus EPS of $4.75 per share for 2026-06-30.
Net Income Rises Year Over Year
Net income for the quarter ended 2026-06-30 was $1.10bn, up 6.48% from $1.03bn for the quarter ended 2025-06-30.
Gross Margin Narrows Sequentially
Gross margin for the quarter ended 2026-06-30 was 85.33%, narrower than the 86.25% recorded for the quarter ended 2025-06-30.
TRIKAFTA Remains Core Revenue Driver
TRIKAFTAKAFTRIO revenue of $103.13bn was 85.9% of consolidated revenue for the period ended 2025-12-31, up 0.7% from $102.39bn in 2024-12-31.
Free Cash Flow Covers Buybacks
Filed free cash flow of $3.194B was 1.58x common-stock repurchases of $2.017B in 2025-12-31.
Price Chart
NASDAQ:VRTX via TradingView
Loading TradingView chart...
Overview
Quarterly income statement data isn't available for this company.
No Data
No annual financial data available.
Financial Fundamentals
Growth, quality, valuation, cash generation, and balance-sheet strength.
Growth
TTM revenue plus current, long-term, forward, and accelerating top-line trends.
Earnings
Trailing EPS, current EPS growth, long-term compounding, surprise, and forward expectations.
Profitability
TTM margin and return metrics that reflect pricing power and business quality.
Cash Flow
TTM free cash flow, growth, margin, and operating-cash conversion quality.
Valuation
Metrics ranked by issuer type, financial state, and input quality.
Forward P/E
Forward P/E is the primary lens because positive expected earnings make the next operating period directly assessable.
Financial Health
Latest-quarter liquidity and leverage checks plus TTM interest coverage.
Shareholder Signals
Capital returns and dilution checks sourced from statements and insider filings.
Peer Comparison
| Ticker | Price | Mkt Cap | EV/EBITDA | Fwd P/E | Rev Growth | Gross Margin | FCF Yield |
|---|---|---|---|---|---|---|---|
VRTXVERTEX PHARMACEUTICALS INC / MA | $541.69 | $137.3B | 26.2x | 28.5x | +10.2% | 86.0% | 2.8% |
Company Profile
About the Company
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Next Earnings Date
Nov 2, 2026
Loading latest news...